Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Context Therapeutics Inc. (CNTX : NSDQ)

• Company Description    Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $1.12 Daily Weekly Monthly 20 Day Moving Average: 440,390 shares Shares Outstanding: 91.88 (millions) Market Capitalization: $102.90 (millions) Beta: 1.94 52 Week High: $2.10 52 Week Low: $0.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.00% -22.10% 12 Week 42.44% 36.53% Year To Date 6.67% -6.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2001 MARKET STREET SUITE 3915 UNIT #15 - PHILADELPHIA,PA 19103 USA ph: 267-225-7416 fax: - ir@contexttherapeutics.com http://www.contexttherapeutics.com

• General Corporate Information    Officers Martin Lehr - Chief Executive Officer and Director Andy Pasternak - Chairman of the Board and Director Jennifer Minai-Azary - Chief Financial Officer Philip Kantoff - Director Karen Smith - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 21077P108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 91.88 Most Recent Split Date: (:1) Beta: 1.94 Market Capitalization: $102.90 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.37 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 54.55% vs. Previous Quarter: -11.11% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -30.93 06/30/25 - -38.80 03/31/25 - -29.78 ROA 09/30/25 - -29.59 06/30/25 - -37.53 03/31/25 - -29.08 Current Ratio 09/30/25 - 13.10 06/30/25 - 19.09 03/31/25 - 48.81 Quick Ratio 09/30/25 - 13.10 06/30/25 - 19.09 03/31/25 - 48.81 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 0.82 06/30/25 - 0.92 03/31/25 - 1.01 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©